MorphoSys Now Sees 2020 Results Above Upper End Of Guidance Range

MorphoSys AG (MOR) said it expects group revenues for 2020 to be 327.7 million euros, which is slightly above the upper end of the guidance range of 317 million euros to 327 million euros.

Group revenues include 18.5 million euros or US$22.0 million revenues from product sales of Monjuvi as well as 42.5 million euros for royalties on net sales of Tremfya.

EBIT or Earnings before Interests and Taxes for 2020 is expected to be 27.4 million euros, and therefore significantly above the upper end of the guidance range of 10 million euros to 20 million euros.

The company noted that it will publish full results on March 15, 2021.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Mallinckrodt plc announced Wednesday that the U.S. Food and Drug Administration or FDA has approved StrataGraft (allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen - dsat) for the treatment of adult patients with thermal burns containing intact dermal elements for which surgical intervention is clinically indicated. Worldwide 5G mobile subscriptions are estimated to exceed 580 million by the end of 2021, according to the Ericsson Mobility Report. With subscriptions increasing at a rate of about a million per day, 5G remains on track to become the fastest adopted mobile generation in history. The growth in subscriptions is being lead by China, North America and the Gulf Cooperation Council markets. Elanco Animal Health Inc. (ELAN) and veterinary biopharmaceutical company Kindred Biosciences, Inc. (KIN) announced Wednesday they have entered into a definitive agreement for Elanco to acquire Kindred for $9.25 per share, or approximately $440 million. The acquisition further accelerates Elanco's...
Follow RTT